10x Genomics CEO sells 30,000 TXG shares
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026. The sales occurred in multiple trades at weighted average prices around $33–$36 per share, as detailed by price ranges in the filing.
The transactions were made under Saxonov’s pre-arranged Rule 10b5-1 trading plan, adopted on November 29, 2025. After these sales, he holds approximately 1,108,380 shares directly, plus additional indirect holdings through the Andromeda Trust, the Y/S Descendants’ Trust, and the Y/S Pot Trust.
Insider Trade Summary 10b5-1
Net Seller: 30,000 shares
Net Sell
7 txns
Insider
Saxonov Serge
Role
Chief Executive Officer
Sold
30,000 shs ($1.03M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 8,527 | $33.289 | $284K |
| Sale | Class A Common Stock | 9,991 | $34.2815 | $343K |
| Sale | Class A Common Stock | 9,821 | $35.3159 | $347K |
| Sale | Class A Common Stock | 1,661 | $36.1646 | $60K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 1,108,380 shares (Direct);
Class A Common Stock — 284,921 shares (Indirect, See footnote)
Footnotes (8)
- F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3. This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4. This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- F7. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- F8. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Key Figures
Shares sold: 30,000 shares
Sale price (weighted average example): $33.2890 per share
Sale price (weighted average example): $36.1646 per share
+4 more
7 metrics
Shares sold
30,000 shares
Total net sales of Class A common stock on June 22, 2026
Sale price (weighted average example)
$33.2890 per share
One reported weighted average sale price range $32.75–$33.74
Sale price (weighted average example)
$36.1646 per share
One reported weighted average sale price range $35.98–$36.24
Direct holdings after transactions
1,129,853 shares
Class A common stock held directly by Serge Saxonov after June 22, 2026 sales
Andromeda Trust holdings
71,644 shares
Class A common stock held indirectly via Andromeda Trust
Y/S Descendants’ Trust holdings
213,250 shares
Class A common stock held indirectly via Y/S Descendants’ Trust
Y/S Pot Trust holdings
27 shares
Class A common stock held indirectly via Y/S Pot Trust
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Andromeda Trust, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Andromeda Trust financial
"The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee."
Y/S Descendants' Trust financial
"The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee."
Y/S Pot Trust financial
"The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did 10x Genomics (TXG) CEO Serge Saxonov report?
Serge Saxonov reported selling 30,000 shares of 10x Genomics Class A common stock in open-market transactions on June 22, 2026. These trades were executed in multiple lots at several price ranges disclosed in the filing.
Was the 10x Genomics (TXG) CEO’s stock sale under a Rule 10b5-1 plan?
Yes. A footnote explains the transactions were effected pursuant to Serge Saxonov’s Rule 10b5-1 trading plan adopted on November 29, 2025. Such pre-arranged plans schedule trades in advance, making the timing more routine.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates